Abstract:In this issue of Endoscopy , Gonzalez et al. present the first double-blind randomized controlled trial to compare the efficacy of gastric peroral endoscopic myotomy (G-POEM) versus botulinum toxin injection (BTI) for the treatment of refractory gastroparesis [1]. Gastric peroral endoscopic myotomy (G-POEM) was first introduced in 2013 as an alternative option for patients with refractory gastroparesis [2]. Recently, two clinical trials, a large multicenter prospective trial by Vosoughi et al. [3] and a randomized sham-controlled trial by Martinek et al. [4], have evaluated the use of G-POEM in refractory gastroparesis and demonstrated a clinical success rate of 56%–70% at 12 months, with low rates of adverse events. Despite these promising results, G-POEM remains a technically challenging procedure, available only in expert centers, while BTI is widely available. Previously no study had directly compared the two endoscopic pylorus-directed therapies. In this study, Gonzalez et al. enrolled 40 patients with at least a 1-year history of gastroparesis, refractory to at least 6 months of optimal medical therapy. Clinical success was defined as a >1-point decrease in the total Gastroparesis Cardinal Symptom Index (GCSI) score. Although the authors demonstrated a numerically higher rate of clinical success on intention-to-treat analysis in the G-POEM group compared with the BTI group at 3 months (65% vs. 40%; P =0.10), statistical significance was not met. Medium-term durability was maintained in both groups, with clinical success rates at 12 months in the G-POEM and BTI groups of 60% and 40%, respectively ( P =0.20). Gastric emptying at 3 months improved in 72% of the G-POEM group compared with 50% of the BTI group ( P =0.17). "While G-POEM was not shown to be superior to BTI, it remains an effective and safe option in expert centers." The major differences between the current study and the aforementioned studies are worth noting. Gonzales et al. demonstrated a clinical success rate slightly lower than that of Martinek et al., but higher than that of Vosoughi et al. This is likely multifactorial. First, Martinek et al. had the highest proportion of diabetic patients, in whom G-POEM has been shown to be more effective [4] [5]. We now know that the largest etiologic group is in fact idiopathic [6], and therefore the study of Gonzalez et al. may be more reflective of real-world outcomes. Second, the definition of clinical success was different across the studies. Vosoughi et al. defined clinical success as a ≥1-point decrease in the total GCSI, with >25% decrease in at least two of the subscales. Martinek et al. defined treatment success as a decrease of ≥50% in the total GCSI score. The current study modified their definition of clinical success from a decrease in GCSI of >0.6 to a decrease of >1, reflecting the rapidly evolving literature on G-POEM from the time of study conception to publication. These diverse definitions of clinical success contribute to the variable findings in each paper, and clearly highlight a need to standardize objective evaluation of treatment response. Despite an essentially negative outcome, the study of Gonzalez et al. is not without noteworthy findings. It confirms G-POEM to be at least modestly effective, durable, and safe for the treatment of refractory gastroparesis. The study should be commended for its many strengths, which include its robust double-blind trial design, which is of even greater importance given the functional nature of gastroparesis. Furthermore, the group used the validated GCSI score and quality of life indicators, including the GIQLI and SF-12. Follow-up was vigorous, with four visits in the first 12 months and the use of gastric emptying studies before and at 3 months post-procedure. However, limitations should also be noted. First, as discussed earlier, the group adjusted the definition of treatment response in line with the evolving literature, but adopting a more rigorous efficacy definition may have resulted in a study underpowered to demonstrate statistical significance. Second, a gastric emptying study was used as an objective marker of treatment response. Gastroparesis is however a heterogeneous disease and the ideal measure of response is unknown. The accepted "gold standard" of diagnosis – i.e. delayed solid gastric emptying – is often bidirectionally labile (i.e. potentially worsening or improving over time) and can frequently occur independently of changes in symptoms [7]. Pyloric distensibility measurements using a functional lumen imaging probe are limited and still evolving in gastroparesis, but are gaining momentum. Both pyloric diameter and the distensibility index have been shown to increase after G-POEM and may be associated with short- -Abstract Truncated-

Gastric Peroral Endoscopic Myotomy (G-Poem) As A Promising Therapy For Functional Delayed Gastric Emptying

Gastric Peroral Endoscopic Myotomy (G-POEM) As a Treatment for Refractory Gastroparesis: Long-Term Outcomes

Efficacy and Safety of Gastric Per-Oral Endoscopic Myotomy (G-POEM)

Efficacy and safety of gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis: 3-year follow up results

Gastric peroral endoscopic myotomy for gastroparesis: A systematic review of efficacy and safety.

Role of gastric peroral endoscopic myotomy (GPOEM) in chronic gastroparesis management after pancreas transplantation

S1568 Multicenter Study of Safety and Efficacy of Inpatient Gastric Peroral Endoscopic Myotomy (G-POEM) for Treatment of Refractory Gastroparesis

A long-term follow-up study of gastric peroral endoscopic myotomy (G-POEM) in a large cohort of patients with postsurgical gastroparesis

Applications of gastric peroral endoscopic myotomy in the treatment of upper gastrointestinal tract disease

Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group

Pyloric-directed therapy for gastroparesis: to cut or to relax?

Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis

S2308 Predictive Value of Gastric Myoelectrical Activity in Patient Satisfaction after Gastric Per-Oral Myotomy

Short-term symptomatic outcomes of GERD in patients with gastroparesis after gastric per oral endoscopic pyloromyotomy

Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial

Long-term efficacy (at and beyond 1 year) of gastric peroral endoscopic myotomy for refractory gastroparesis: A systematic review and meta-analysis

Filling the Gap: Safety of Per-Oral Endoscopic Myotomy Attested by Evidence

Peroral endoscopic myotomy and its use in non-achalasia disorders

S3718 Acute Upper GI Hemorrhage Following G-POEM: A Rare Case Of Delayed Submucosal Bleeding Resulting in Necrosis and Disruption of Mucosal Flap

Short-term outcomes of double versus single pyloromyotomy at peroral endoscopic pyloromyotomy in the treatment of gastroparesis (with video)

S2341 New Endoscopic Approaches Versus Conventional Surgical Interventions in the Management of Refractory Gastroparesis: A Network Meta-Analysis